Politwoops
Explore the Tweets They Didn't Want You to See
Politwoops tracks deleted tweets by public officials, including people currently in office and candidates for office.
Politwoops tracks deleted tweets by public officials, including people currently in office and candidates for office. If you think we're missing someone, please email us with their name, state, political party, office they hold or are seeking and, of course, their Twitter handle.
Are your deleted tweets displayed here but you think they shouldn't be? Here's how to let us know.
This West Michigan job growth would be hurt by the medical device tax. A two year delay is a positive development, but we to fully repeal the MDT. https://t.co/2cwH32XJf7 QT @TheRightPlaceGR: Did you know these West Michigan medical device manufacturing stats? #WestMichiganWednesday https://t.co/9qxikl8yg1)
Tell_Michelle_ (R-Nev.)
@Tell_Michelle_
RT @Tell_Michelle_: There will always be doubters, haters and naysayers. Here’s to proving them all wrong. Here’s to making a real diff… https://t.co/DDY6Z86Z3Y
SteveFDA (R-D.C.)
@SGottliebFDA
My remarks at #AHIP today highlight substantial public health benefit of a competitive market for biosimilars; strong market incentives are critical to future biosimilar development in same way incentives are key for development of innovator drugs https:/
SteveFDA (R-D.C.)
@SGottliebFDA
Kabuki drug-pricing constructs obscure profit taking across supply chain, expose consumers to higher costs and actively discourage competition. The complexity and opacity of these schemes help conceal their corrosion on system, and impact on patients. htt
AP4Liberty (R-Mo.)
@AP4Liberty
RT @AllmanReport: In the past few days, @PeggyHubbard20 MO. GOP Candidate for US Senate @AP4Liberty and @gatewaypundit have been bann… https://t.co/KBavdL9ksn
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA is invested in ensuring the biosimilar pathway works and facilitating a robust market for these products. We discourage practices that reduce incentive for sponsors to invest in the development of biosimilars. https://t.co/VfyO1nOt1f
SteveFDA (R-D.C.)
@SGottliebFDA
More transparent pricing signals would encourage rapid market uptake of lower cost products, and force manufacturers to better establish the real value of their products relative to price, including through innovative payment contracts. https://t.co/VfyO1
SteveFDA (R-D.C.)
@SGottliebFDA
If we’re not able or willing to support the development of biosimilar market as it matures then the resulting competition we seek, and that patients need, will be derailed. https://t.co/VfyO1nOt1f
WATCH LIVE: An Overview of the NASA Budget for Fiscal Year 2019 https://t.co/ILHFEQR6qG
SteveFDA (R-D.C.)
@SGottliebFDA
At #FDA, we’re working closely with @SecAzar on crafting policy to improve competition, access, and opportunity for patients to benefit from safe, effective, and lower cost biosimilar alternatives. https://t.co/VfyO1nOt1f
Are your deleted tweets displayed here but you think they shouldn't be? Here's how to let us know.